(MM) (TKMR) Quote

from Whitefort's 13D filed today: "The Reporting Persons have conveyed their view to the Issuer’s Board of Directors (the “Board”) that the current market price of the Shares does not reflect the Issuer’s intrinsic value. The Reporting Persons have requested that the Board immediately terminate the Issuer’s ATM program and explore all strategic options for the Issuer’s hepatitis B virus (HBV) portfolio. The Reporting Persons hope to continue to work constructively and collaboratively with the Board on these critical initiatives and intend to actively engage with shareholders and others regarding their views."

ABUS under $3

TWTR
Twitter Inc
53.70
0.00 (0.00%)
Volume:

ABUS new 52 hi

looking a little better today; i guess it's going to be slow and steady and not the rocket on markman day like i hoped. i think this is looking really good med-long term on the litigation from after that markman ruling

also, looking forward to EASL in june

ABUS
Arbutus Biopharma Corporation
3.00
0.08 (2.74%)
Volume: 1,253,240
Day Range: 2.86 - 3.11
Bid: 2.99
Ask: 3.00
Last Trade Time: 9:56:51 AM EDT
Total Trades: 3,890

ABUS
Arbutus Biopharma Corporation
3.00
0.08 (2.74%)
Volume: 1,253,240
Day Range: 2.86 - 3.11
Bid: 2.99
Ask: 3.00
Last Trade Time: 9:56:51 AM EDT
Total Trades: 3,890

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
03/05/2024 04:48:49 PM

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
03/05/2024 04:48:49 PM

Arbutus to Participate in Two Upcoming Investor Conferences
03/08/2024 07:30:00 AM
Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
03/05/2024 04:48:49 PM

Arbutus Biopharma Announces Claim Construction Ruling in its Ongoing Patent Infringement Lawsuit Against Moderna
04/04/2024 08:30:49 AM
Arbutus to Participate in Two Upcoming Investor Conferences
03/08/2024 07:30:00 AM
Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
03/05/2024 04:48:49 PM

07:15 AM EDT, 04/04/2024 (MT Newswires) -- A US court ruled against Moderna (MRNA) in a patent infringement case by Arbutus (ABUS) over its COVID-19 vaccines, Reuters reported Wednesday.

US District Judge Mitchell Goldberg interpreted the patents in ways that favored Arbutus' case and hurt Moderna', Reuters reported.

Arbutus sued Moderna in 2022, claiming the company's COVID-19 vaccine impinged on its patents for lipid nanoparticles that shield the vaccine's mRNA from the body's immune system.

Moderna and Arbutus did not immediately respond to MT Newswires' requests for comment.

Watching all 3 stocks. $ABUS is kind of moving...

was going to take all '3' to explode imo..

Yes, I'm trying to read it myself

decision is out; looks like arbutus won '2' and moderna '1' .. please confirm

https://dailycaller.com/2024/03/14/drew-johnson-moderna-covid-vax-patent-infringement-biden-admin/

My bad on post a few weeks ago. When I posted about $MRNA cash position, I didn't do the research I should have done and used what was on cash flow statement and didn't look into long term investments, very sloppy of me. Sorry about that.

In today's release, they are projecting to use $4.3 billion of their cash plus investments during 2024. At 12/31/23 they reported cash plus LT investments of $13.3 billion and project about $9 billion at end of 2024. It will take longer than I thought for them to run out of cash and hopefully $ABUS takes a huge chunk of it. Today MRNA had a surprise profit, and I am still hoping that $ABUS finally cleans their clock for their blatant theft of IP.

Handle on twitter is @DesertDweller93

Great post!

What’s your handle on Twitter?

I've been saying on X for a month or so that $MRNA will be suffering a drop once it becomes known that they have roughly a year's worth of cash left, I just discovered this recently. They are burning almost $7 billion/year and they will report less than that at 12/31/23. That on top of the fact that during the past 3 years, they spent $7 billion in buybacks at prices much higher than current prices, all the way up to $300+. My prediction is major restructuring or significant secondary very soon. I bet they wish they had that cash now instead of overpriced treasury stock but then mgt wouldn't have been able to sell at those inflated covid prices.

Hope $ABUS puts them into bankruptcy, the f'n thieves and I hope ABUS cleans $PFE and Biontech's clock too. They all know they are stealing the tech and just don't care. About time David kicks Goliath's ass again.

A couple bad headlines for MRNA of late. Here is one of todays...

Moderna’s RSV Vaccine May Lose Efficacy Faster Than GSK and Pfizer’s

yes, quite the drop yesterday and today on mrna... g/l!

Puts on $MRNA might be the best play. If they have to pay up to $ABUS I have a feeling it might see a precipitous drop...

MRNA bad news is piling up there...

https://twitter.com/themightyforego/status/1755757415750865356?s=46

And also

Get on Twitter Damn it lol!

wasn't.. will check it out... thanks!!

Also

Are you watching VKTX?

Thanks for pointing this out

interesting (although stock isn't reacting): "Watching Arbutus Biopharma; Hearing Jefferies Issues Note On Arbutus Biopharma On LNP Markman Hearing Saying Judge Favors Company Over Moderna. -BENZINGA"

"Markman Hearing set for February 8, 2024 – court will hear arguments on claim construction and expected to issue its order within 60 days of conclusion of the hearing"

from 1/8/2024 Arbutus presentation...

2,000,000 share block trade woke some people up ...........

"With respect to the Moderna lawsuit, fact discovery is currently on-going with the claim construction hearing scheduled for February 8, 2024. According to the Court Scheduling Order, which was issued on March 21, 2023, the court is expected to issue its claim construction order within 60 days of conclusion of the claim construction hearing."

https://investor.arbutusbio.com/news-releases/news-release-details/arbutus-announces-2024-corporate-objectives-and-provides

from what i'm reading, apparently people are not in love with today's update... 1) moderna trial in 2025 when i think it was expected this year and 2) using 'durvalumab' in a trial instead of their own '101' which some say may mean safety signal seen in '101'(?)

all noise to me; markman is why i came here in the first place......

g/l!

with there being several catalysts, it 'possibly' sets up some safety if only 1 goes bad(?)

I’ll start watching for any unusual options heading into February

ABUS gets 20% of win and then also owns 12%(?) of Genevant as well...

ROIV safer for sure but %-wise ABUS would benefit more......

$ROIV might be the better play however. Will have to look it up again but I think ROIV would receive the majority of any verdict?

No, I myself didn’t realize it. Front screen now, thanks db!

When are you going to set up an account on Twitter!!!

yep

correct; pfizer date not yet set 'but' Moderna has... sorry, if I misinterpreted your post...

I read this wrong. So there are two trails? One against PFE/BNTX and one against MRNA.
Hmmm

A trial date has not been set, but the trial is expected to commence in the first half of 2025. The lawsuit against Pfizer/BioNTech is ongoing and a date for a claim construction hearing has not been set.

Moderna Claims Construction (ie: Markman hearing) 2/8/2024 with decision expected within 60 days; 'this' should be an event for sure.... positive or negative, we'll have to wait and see- g/l!

For now, almost all small biotechs have participated in the melt up to close 2023. We will have to see where 2024 takes us. Their biggest catalyst, the lawsuit with MRNA and BNTX is still a ways away.
But it’s one that is always on my radar.

going to be a busy 1st half of the year here...

https://investor.arbutusbio.com/news-releases/news-release-details/arbutus-announces-2024-corporate-objectives-and-provides

https://www.otcmarkets.com/stock/ABUS

I’ll be watching thanks